Compare BLZE & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLZE | NBP |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.8M | 225.5M |
| IPO Year | 2021 | N/A |
| Metric | BLZE | NBP |
|---|---|---|
| Price | $11.77 | $1.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | $7.60 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 3.3M | 695.4K |
| Earning Date | 05-04-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $145,835,000.00 | N/A |
| Revenue This Year | $10.16 | N/A |
| Revenue Next Year | $10.91 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 14.27 | N/A |
| 52 Week Low | $3.26 | $1.46 |
| 52 Week High | $18.25 | $5.19 |
| Indicator | BLZE | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 41.82 | 46.17 |
| Support Level | $3.93 | $1.67 |
| Resistance Level | $18.25 | $1.95 |
| Average True Range (ATR) | 1.28 | 0.11 |
| MACD | -0.70 | -0.01 |
| Stochastic Oscillator | 0.61 | 17.14 |
Backblaze Inc offers a cloud storage platform designed to help businesses and consumers store, use, and protect their data. The company delivers its services through the Backblaze Storage Cloud platform, a purpose-built, web-scale software architecture operating on commodity hardware. Backblaze's offerings include B2 Cloud Storage, an Infrastructure-as-a-Service (IaaS) solution, and Computer Backup, a Software-as-a-Service (SaaS) solution. Its customer base includes individuals, developers, MSPs, small and medium-sized businesses, and large enterprises across industries, academic institutions, government agencies, and other enterprises. Geographically, the company generates maximum revenue from its business in the United States, followed by the United Kingdom, Canada, and other markets.
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.